Chronic Sialorrhea Market Report 2026

Chronic Sialorrhea Market Overview

• Chronic Sialorrhea market size has reached to $0.76 billion in 2025 • Expected to grow to $1.02 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Growing Research And Development Investments Accelerating Advances In The Market Due To Increasing Focus On Innovation And Therapeutic Advancements • Market Trend: Enhancing Patient Compliance With Non-invasive Treatments For Children • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chronic Sialorrhea Market?

Chronic sialorrhea refers to the persistent excessive production or impaired control of saliva, often associated with neurological conditions such as Parkinson’s disease, cerebral palsy, or ALS. It is managed using pharmacological treatments, botulinum toxin injections, or surgical interventions to improve oral function, reduce complications, and enhance patients' quality of life. The main treatment types of chronic sialorrhea are pharmacological treatments, botulinum toxin injections, surgical interventions, medical devices, and assistive therapies. Pharmacological treatments for chronic sialorrhea involve the use of medications, such as anticholinergics and botulinum toxin injections, to reduce excessive salivation and manage symptoms. These treatments can be administered through various routes, including oral medications, injectable treatments, and topical applications. The patient population receiving these therapies includes both pediatric and adult patients, and the key end users are hospitals and specialty clinics, rehabilitation centers, and homecare settings.

What Is The Chronic Sialorrhea Market Growth Forecast?

The chronic sialorrhea market size is expected to see strong growth in the next few years. It will grow to $1.02 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to increasing approvals for new injectable therapies, rising focus on home-based care solutions, expansion of assistive oral devices, growing geriatric population, increasing investment in neurological disorder management. Major trends in the forecast period include increasing use of botulinum toxin therapies, rising adoption of non-invasive management approaches, growing focus on neurology-linked sialorrhea care, expansion of assistive medical devices, enhanced emphasis on quality-of-life improvement.

Global Chronic Sialorrhea Market Segmentation

1) By Treatment Type: Pharmacological Treatments, Botulinum Toxin Injections, Surgical Interventions, Medical Devices And Assistive Therapies 2) By Route Of Administration: Oral Medications, Injectable Treatments, Topical Applications 3) By Patient Population: Pediatric Patients, Adult Patients 4) By End-User: Hospitals And Specialty Clinics, Rehabilitation Centers, Homecare Settings Subsegments: 1) By Pharmacological Treatments: Anticholinergic Medications, Antidepressants, Alpha-Adrenergic Agonists, Salivary Gland Modulators 2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox), Botulinum Toxin Type B (Myobloc), Localized Salivary Gland Injections 3) By Surgical Interventions: Sialendoscopy, Salivary Gland Duct Dilation Or Stenting, Parotid Duct Surgery, Submandibular Gland Removal (Sialadenectomy) 4) By Medical Devices And Assistive Therapies: Oral Dryness Devices, Salivary Stimulation Devices, Lip And Mouth Exercises, Artificial Salivary Glands

What Are The Drivers Of The Chronic Sialorrhea Market?

The growing research and development activities are expected to propel the growth of the chronic sialorrhea market going forward. Research and development activities refer to systematic efforts focused on creating new innovations or improving existing products, technologies, or processes through scientific research and experimentation. Increasing research and development activities is driven by the need for continuous innovation to help organizations create advanced solutions that keep them competitive in evolving markets. Research and development activities help address chronic sialorrhea by enabling the discovery and improvement of targeted therapies, delivery systems, and diagnostic approaches that can more effectively reduce excessive drooling and improve patient quality of life. For instance, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on research and development (R&D) increased to £17.4 billion ($22.1 billion) in 2023, up from £16.1 billion ($20.45 billion) in 2022, marking an 8.2% rise. Therefore, the growing research and development activities are driving the growth of the chronic sialorrhea industry. The increasing prevalence of neurodegenerative disorders is expected to propel the growth of the chronic sialorrhea market going forward. Neurodegenerative disorders refer to a group of diseases characterized by the progressive degeneration or death of nerve cells (neurons) in the brain and spinal cord. The rising neurodegenerative disorders are due to genetic factors and family history, environmental factors, better understanding of disease mechanisms, chronic health conditions, and social and psychological factors. Chronic sialorrhea is a common complication of neurodegenerative disorders like Parkinson’s disease and ALS, necessitating targeted treatments to prevent aspiration, enhance oral function, and improve patient comfort. For instance, in September 2023, according to Parkinson's UK, a UK-based charitable company, approximately 153,000 individuals in the UK are currently living with Parkinson’s, and with an aging population, this number is projected to increase by 20% to an estimated 172,000 by 2030. Therefore, the increasing prevalence of neurodegenerative disorders will drive the growth of the chronic sialorrhea industry.

Key Players In The Global Chronic Sialorrhea Market

Major companies operating in the chronic sialorrhea market are Pfizer Inc, Ipsen Pharmaceuticals Inc, Aurobindo Pharma Limited, Hugel Inc, Medy‑Tox Inc, Granules India Limited, US WorldMeds LLC, Merz Therapeutics GmbH, Taj Pharma India Limited, Teva Pharmaceutical Industries Ltd, Bayer AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lundbeck A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Novartis AG, Astellas Pharma Inc, Viatris Inc, Sandoz International GmbH, Proveca Limited, NeuroHealing Pharmaceuticals Inc, Solstice Neurosciences Inc, Gufic Biosciences Limited

Global Chronic Sialorrhea Market Trends and Insights

Major companies operating in the chronic sialorrhea market are focusing on developing innovative treatments, such as oral solutions, to improve patient compliance and provide non-invasive alternatives for managing chronic sialorrhea in children, enhancing safety and effectiveness while reducing side effects. An oral solution is a liquid medication formulated for oral administration, containing the active ingredient dissolved in a solvent, designed for easy ingestion. For instance, in February 2023, Proveca Pharma Ltd., a UK-based pharmaceutical company, launched Sialanar (glycopyrronium bromide) in France for the treatment of severe chronic sialorrhea in children with neurological disorders. A key feature of this product is its liquid formulation, designed for ease of administration and accurate dosing, making it particularly beneficial for pediatric patients who struggle with solid medications. It offers a well-established safety and efficacy profile, helping to improve quality of life by reducing excessive drooling, which is a common challenge in neurodevelopmental conditions like cerebral palsy.

Regional Outlook

North America was the largest region in the chronic sialorrhea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Sialorrhea Market?

The chronic sialorrhea market consists of revenues earned by entities by providing services such as medical treatment services, non-surgical interventions, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic sialorrhea market also includes sales of neurostimulation devices, resection kits, absorbent clothing and bibs, and customized oral prosthetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Sialorrhea Market Report 2026?

The chronic sialorrhea market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic sialorrhea industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.